The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer

The Chinese University of Hong Kong

Status and phase: Completed; Phase 3

Conditions: Squamous Cell Carcinoma of Esophagus

Treatments: Drug: Andrographis Paniculata

Study type: Interventional

Funder types: Other

Identifiers

NCT04196075

CRE-2017.616

Details and patient eligibility

About

This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on palliative management of patients with advanced or metastatic esophageal cancer. A total of 30 patients with locally advanced or metastatic squamous esophageal cancer will be recruited for the trial.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Aged over 18
2. Locally advanced esophageal cancer with invasion or adherent to surrounding organs including trachea, recurrent laryngeal nerves and descending aorta;
3. Presence of distant metastasis;
4. Extensive lymph node metastasis to beyond surgical therapy

Exclusion criteria

1. Patients who cannot receive palliative stenting for dysphagia or under other conventional treatment including chemotherapy or chemoradiotherapy
2. Patients who are not willing to receive Chinese herbal medicines
3. Patients who do not consent for the study

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Andrographis Paniculata treatment

Experimental group

Description:

Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard

Treatment:

Drug: Andrographis Paniculata